-
1
-
-
18544380239
-
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
-
[1] Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
-
(2002)
Nat. Med.
, vol.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
-
2
-
-
0037126021
-
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
-
[2] Iwai, Y., Ishida, M., Tanaka, Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99:19 (2002), 12293–12297.
-
(2002)
Proc. Natl. Acad. Sci. U.S.A.
, vol.99
, Issue.19
, pp. 12293-12297
-
-
Iwai, Y.1
Ishida, M.2
Tanaka, Y.3
-
3
-
-
84859158384
-
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
-
[3] Topalian, S.L., Drake, C.G., Pardoll, D.M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24 (2012), 207–212.
-
(2012)
Curr. Opin. Immunol.
, vol.24
, pp. 207-212
-
-
Topalian, S.L.1
Drake, C.G.2
Pardoll, D.M.3
-
4
-
-
84924901863
-
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
-
[4] Rizvi, N.A., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 3 (2015), 257–265.
-
(2015)
Lancet Oncol.
, vol.3
, pp. 257-265
-
-
Rizvi, N.A.1
-
5
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
[5] Brahmer, J., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373:2 (2015), 123–135.
-
(2015)
N. Engl. J. Med.
, vol.373
, Issue.2
, pp. 123-135
-
-
Brahmer, J.1
-
6
-
-
84936749833
-
Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer
-
[6] Gettinger, S.N., et al. Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J. Clin. Oncol. 33 (2015), 2004–2012.
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 2004-2012
-
-
Gettinger, S.N.1
-
7
-
-
84862903106
-
Safety and activity of anti–PD-L1 antibody in patients with advanced cancer
-
[7] Brahmer, J., et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.1
-
8
-
-
84958181736
-
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
-
[8] Villadolid, J., Asim, A., Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl. Lung Cancer Res. 4:5 (2015), 560–575.
-
(2015)
Transl. Lung Cancer Res.
, vol.4
, Issue.5
, pp. 560-575
-
-
Villadolid, J.1
Asim, A.2
-
9
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
[9] Topalian, S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32 (2014), 1020–1030.
-
(2014)
J. Clin. Oncol.
, vol.32
, pp. 1020-1030
-
-
Topalian, S.L.1
-
10
-
-
77954019731
-
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
-
[10] Wang, J., Okazaki, I.M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol. 22 (2010), 443–452.
-
(2010)
Int. Immunol.
, vol.22
, pp. 443-452
-
-
Wang, J.1
Okazaki, I.M.2
Yoshida, T.3
Chikuma, S.4
Kato, Y.5
Nakaki, F.6
-
11
-
-
84997637224
-
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
-
[11] Läubli, H., et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer, 3, 2015, 11.
-
(2015)
J. Immunother. Cancer
, vol.3
, pp. 11
-
-
Läubli, H.1
-
12
-
-
84922392615
-
Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance
-
[12] Jordan, J.H., et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging 7:November (6) (2014), 872–879.
-
(2014)
Circ. Cardiovasc. Imaging
, vol.7
, Issue.November (6)
, pp. 872-879
-
-
Jordan, J.H.1
-
13
-
-
40949103615
-
Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy
-
[13] Fallah-Rad, N., et al. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J. Cardiovasc. Magn. Reson., 10, 2008, 5.
-
(2008)
J. Cardiovasc. Magn. Reson.
, vol.10
, pp. 5
-
-
Fallah-Rad, N.1
-
14
-
-
84973281958
-
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
-
(Feb 21 [Epub ahead of print])
-
[14] Gulati, G., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J., 2016 (Feb 21 [Epub ahead of print]).
-
(2016)
Eur. Heart J.
-
-
Gulati, G.1
-
15
-
-
84939227614
-
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of Programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers
-
[15] Carbognin, L., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of Programmed Death-Ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 6, 2015, e0130142.
-
(2015)
PLoS One
, vol.6
, pp. e0130142
-
-
Carbognin, L.1
|